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Over thirty years ago, Helen Stone and colleagues compared the effects of local tumor
irradiation in immunocompetent and T cell deficient mice, providing the first evidence that
tumor response to radiotherapy is impaired in the absence of a normal T cell repertoire. In
the following three decades there has been an exponential growth in understanding T cells
and the complex molecular mechanisms that regulate their activation, migration to tumors
and effector functions. We now also know that tumor progression is intrinsically linked
to the development of multiple immunosuppressive mechanisms that allow cancer cells
to escape immune control. Recent evidence about the role of T cells in determining the
prognosis and outcome of patients at any clinical stages of cancer has been instrumental
in re-directing the concept of immunosurveillance and immunoediting from the realm of
preclinical models to the reality of clinical observations. Importantly, cell death induced
by standard anti-cancer therapies like chemotherapy and radiation has been demonstrated
to involve the immune system and, in certain specific settings, enable a specific immune
response. It is, therefore, not surprising that the last few years have seen an increase
in investigations exploring how to harness the ability of radiation to induce anti-tumor
immune responses. We will review here the experimental evidence that anti-tumor T cells
are key players in tumor control achieved by radiotherapy. The effects of radiation on the
tumor that have been shown to enhance the priming and effector phases of anti-tumor
immunity will be discussed. Finally, we will highlight promising combinations of immune
response modifiers that enhance T cell function with radiotherapy which are being tested
in the clinic.
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INTRODUCTION
Ionizing radiation has been employed as a cancer treatment based
on its cytocidal effects, and the response to radiotherapy linked
mostly to the delivery of irreparable DNA damage to tumor cells.
Therefore, research to improve the efficacy of radiotherapy has
been dominated by studies of the mechanisms of DNA repair,
their regulation in normal and neoplastic cells, and the tumor
cell factors that affect radiosensitivity, such as the phase of the
cell cycle. While in vitro these parameters are determinants of
the inhibition of tumor cell growth by radiation, in vivo they are
essential but not sufficient to explain the response of a tumor to
local radiotherapy. In fact, a report published in 1979 by Helen
Stone and colleagues demonstrated that in vivo, factors extrinsic
to the cancer cell are key determinants of tumor radiosensi-
tivity (Stone et al., 1979). Instead of studying the response of
human tumor xenografts that grow only in immunocompro-
mised mice, a mouse tumor was injected in syngeneic animals.
Radiosensitivity was then compared in immunocompetent and T
cell-deficient animals. The difference was striking: tumors grow-
ing in mice that lacked T cells required over 60 Gy to achieve
the same tumor control obtained with 30 Gy in immunocom-
petent mice. More than thirty years later, the key role of T cells
as anti-tumor effectors is unquestionable in experimental mouse
models as well as in humans. There is evidence from clinical
trials that adoptive transfer of tumor-specific T cells can elimi-
nate tumors even at advanced stages (Porter et al., 2011; Restifo
et al., 2012). Significant progress has also been made in under-
standing how a treatment considered immunosuppressive such as
radiation can induce anti-tumor T cells, as reviewed in this arti-
cle. While the clinical evidence of systemic anti-tumor responses
from local radiotherapy is rare, the uncommon observation of
tumor regression outside of the radiation field was recognized
by R. H. Mole and named, in 1953 as abscopal effect from the
latin “ab scopus,” i.e., away from the target (Mole, 1953). Based
on the hypothesis that the abscopal effect is due to radiation-
mediated induction of anti-tumor T cells (Demaria et al., 2004),
interventions that improve T cell activation have shown abscopal
effects when combined with radiotherapy in mice and humans
(Demaria et al., 2005; Formenti and Demaria, 2009; Postow et al.,
2012).
To understand the role of T lymphocytes in the tumor response
to radiotherapy it is useful to review the evidence on the reciprocal
influence that tumor and immune cells have on each other during
tumor progression.
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TUMOR-HOST IMMUNE SYSTEM: A DYNAMIC
EQUILIBRIUM
The fundamental task of the immune system is to maintain tissue
homeostasis. This is an active process that requires a delicate bal-
ance between tolerance and active surveillance to detect any tissue
change that is potentially dangerous. Since tissue turnover and
physiological remodeling, for example in the breast post-weaning,
are often associated with significant cell death, the immune sys-
tem has developed sensors to distinguish it from pathogenic cell
death. A key class of receptors devoted to triaging cell death
are pattern recognition receptors (PRR). Expressed by innate
immune cells they bind to pathogen-associated molecular pattern
(PAMP) molecules derived from infectious agents and damage-
associated molecular pattern (DAMP) molecules derived from
cells dying a stressful death (Janeway and Medzhitov, 2002; Zeh
and Lotze, 2005; Mills, 2011). The ability to resist cell death
has been identified as one of the hallmarks of cancer (Hanahan
and Weinberg, 2000), suggesting that, in addition to resulting
in tumor growth, this property may also account for a failure
of recognition of the pathogenic features of transformed cells
by the immune system. However, there is plenty of evidence to
the contrary and, in fact, immune recognition of cancer cells is
so common that the ability to evade immune destruction has
been increasingly recognized as an essential biological capabil-
ity required by tumors in order to become clinically apparent
(Hanahan and Weinberg, 2011). The cancer immunoediting the-
ory provides a rationale for this apparent paradox (Dunn et al.,
2002).
Neoplastic transformation is invariably associated with
genomic instability and cell stress. Genomic instability leads to
the generation of neoantigens-containing epitopes that can be
recognized by T cells (Segal et al., 2008) and cell stress leads
to the expression of molecules such as members of the family
of NKG2D ligands that are recognized by natural killer (NK),
γδ T cells and effector CD8 T cells (Diefenbach et al., 2000;
Hayakawa et al., 2002). Local disruption of the stroma and
of normal tissue architecture generates danger signals in the
form of DAMPs, including degraded extracellular matrix com-
ponents (e.g., heparin sulfate, hyaluronan) (Lotze et al., 2007)
that attract innate immune cells. Recognition of the stressed
neoplastic cells by NK or other innate immune cells results in
production of interferon (IFN)-γ, a cytokine shown to play a
key role in immunosurveillance against tumors (Street et al.,
2001; Dunn et al., 2006). Killing of the neoplastic cells by NK
cells or macrophages activated by IFN-γ to produce cytocidal
reactive oxygen and nitrogen species, eventually leads to cross-
presentation by dendritic cells (DC) of antigens from the dying
tumor cells to T cells and activation of the adaptive immune sys-
tem. Tumor-specific T cells may be able to completely destroy
the incipient tumor, thus functioning as an extrinsic tumor sup-
pressor mechanism that reduces the incidence of spontaneous
and carcinogen-induced tumors. This is supported by unequiv-
ocal evidence in experimental models and indirect evidence in
humans with various immunodeficiencies [reviewed in Dunn
et al. (2004) and Vesely et al. (2011)]. However, if complete
elimination of genomically unstable cells is not achieved, the
immunological pressure results in selection of clones of neoplastic
cells that have acquired, via mutations or epigenetic changes,
resistance to immune rejection, i.e., are “edited” by the immune
system to become poorly immunogenic. This transition from
elimination to escape can occur directly, or sometimes can occur
after a long period of equilibrium, during which the immune
response is able to prevent or limit the progression of cancer.
The concept of equilibrium, initially formulated to explain clin-
ical observations of occult tumors and tumor dormancy (Myron
Kauffman et al., 2002; MacKie et al., 2003), has been confirmed
in experimental models: depletion of T cells leads to growth
of occult tumors that are more immunogenic, indicating that
much of the immunoediting occurs during the equilibrium phase
(Koebel et al., 2007). Importantly, recent evidence demonstrates
that CD8 T cells play a key role in “editing out” strongly immuno-
genic tumor antigens (DuPage et al., 2012; Matsushita et al.,
2012).
The same property that allows tumors to escape immune con-
trol may become their Achille’s Heel. Tumors with high levels
of genomic instability due to microsatellite instability (MSI) are
prone to generate novel tumor antigens. They are often highly
infiltrated by T cells and their carriers often enjoy better clini-
cal outcomes, an association suggestive of better immune control
(Buckowitz et al., 2005; Chiaravalli et al., 2006). Importantly, the
association between infiltration by CD8 T cells and improved
prognosis is not exclusive to tumors with MSI (Zhang et al., 2003;
Galon et al., 2006; Pagès et al., 2010). This observation suggests
that the degree and type of immune response matters at every
stage of tumor progression, including metastatic disease. For
example, the ability of immunotherapeutic strategies to improve
survival of patients with metastatic melanoma (Hodi et al., 2010)
indicates that even in advanced stages, when tumors have escaped
immune control, it is possible to enhance anti-tumor T cell reac-
tivity to revert to a phase of equilibrium, even in the presence of
more extensive tumor burden.
Tumor’s escape from immune control is a complex process,
which does not only occur via antigenic loss. To avoid immune
rejection tumors exploit multiple pathways that physiologically
maintain immune tolerance to “self” and protect healthy tissues
from immune destruction during acute inflammatory reactions.
The recruitment of suppressive, tolerogenic and regulatory innate
and adaptive immune cells, the secretion of immune suppres-
sive cytokines and the induction of dysfunctional differentiation
of T cells can be seen in most, if not all tumors [reviewed in
Demaria (2012)]. In addition, cancer cells downregulate major
histocompatibility complex (MHC) class I molecules that are
required for recognition by CD8 T cells (Chang and Ferrone,
2007), and upregulate immunosuppressive receptors that pre-
clude their destruction by T cells (Dong et al., 2002). The tumor
vasculature also presents multiple barriers to T cell infiltra-
tion, through an abnormal architecture and a relative paucity of
endothelial adhesion molecules (Chen et al., 2003). Overall, the
tumor microenvironment evolves into a protective hub for the
neoplastic cells, that actively prevents tumor rejection. In this
context, ionizing radiation acts as a modifier of the microen-
vironment with the potential to switch the immunosuppres-
sive hub into an immunogenic one (Demaria and Formenti,
2007).
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ROLE OF THE IMMUNE SYSTEM IN RESPONSE TO
LOCAL RADIOTHERAPY
Although radiation has been known to have pro-inflammatory
and immunomodulatory effects for a long time (McBride et al.,
2004), it is only recently that some of these changes have been elu-
cidated at a molecular level. These studies have provided evidence
for the counterintuitive concept that local radiotherapy, rather
than suppressing anti-tumor immunity, can promote it. A series
of important findings in relation to the main barriers to immune
rejection that are affected by radiation have emerged.
As mentioned above, the correct assessment of cell death by
innate immune cells as “dangerous” or “non-dangerous” dic-
tates which downstream pathways are triggered to either acti-
vate adaptive immunity or maintain tolerance. The traditional
dichotomy of cell death as apoptotic and non-inflammatory
versus necrotic and inflammatory has been challenged by the
demonstration that apoptotic death can be associated with release
of pro-inflammatory and danger signals (Galluzzi et al., 2007).
The stressful death of cancer cells induced by some types of
chemotherapy and by ionizing radiation can be quite immuno-
genic and promote the cross-presentation of tumor-derived anti-
gens by DC to T cells, leading to development of anti-tumor
responses (Ma et al., 2010; Zitvogel et al., 2010). Among the
three molecular signals identified as critical for the successful
induction of immunogenic cell death, both, translocation of cal-
reticulin (CRT) to the surface of the dying cell and release of
high-mobility group protein B1 (HMGB1), which binds to the
PRR Toll-Like Receptor (TLR) 4, are induced by ionizing radi-
ation (Apetoh et al., 2007; Obeid et al., 2007). The third signal,
active release of ATP by cells committed to apoptotic death, which
is required to activate the NLRP3 inflammasome (Ghiringhelli
et al., 2009) is still awaiting confirmation in irradiated cells.
Given recent evidence that autophagy is required for ATP release
(Michaud et al., 2011), and that ionizing radiation promotes
autophagy (Rieber and Rieber, 2008; Rodriguez-Rocha et al.,
2011), this third signal is likely to be generated by radiotherapy
when autophagy precedes cell death. Overall, experimental evi-
dence supports the contention that radiation can induce a tumor
cell death that is perceived by the immune system as dangerous
and, therefore, generates an in situ cancer vaccine.
Once activated, T cells have to be able to home to and infil-
trate the tumor. Radiation has been shown to promote this
process in multiple ways. For instance, radiation-induced remod-
eling of the abnormal tumor vessels, resulted in efficient tumor
infiltration by adoptively transferred anti-tumor T cells in a spon-
taneous mouse tumor model (Ganss et al., 2002). In a murine
experimental model of melanoma, up-regulation of vascular cell
adhesion molecule (VCAM)-1 induced by radiation increased
infiltration by T cells, in a process requiring IFN-γ produc-
tion (Lugade et al., 2005, 2008). Our group demonstrated in a
poorly immunogenic mouse carcinoma that radiation-induced
up-regulation of the chemokine CXCL16 was required for the effi-
cient recruitment to the tumor of CXCR6+ effector CD8 T cells,
resulting in optimal tumor inhibition (Matsumura et al., 2008).
Other important effects of radiation include the up-regulation
of MHC class I molecules, adhesion molecules, NKG2D ligands,
and Fas/CD95, enhancing the ability of effector T cells to bind
to and kill the cancer cells (Hareyama et al., 1991; Gaugler et al.,
1997; Chakraborty et al., 2003, 2004; Garnett et al., 2004; Gasser
et al., 2005; Kim et al., 2006; Newcomb et al., 2006; Reits et al.,
2006). Thus, radiation is a significant modifier of tumor microen-
vironment with specific effects that facilitate tumor rejection
(Figure 1).
Despite the multiple pro-immunogenic effects, radiation by
itself is usually insufficient to generate strong and lasting T cell
responses that in addition to contributing to eradicate the irra-
diated tumor can control the growth of established metastases.
Multiple immunosuppressive pathways make it very difficult to
overcome these barriers by radiotherapy alone, in the absence
of additional interventions. However, addition of antibodies to
block a negative regulator of T cell activation, the checkpoint
receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-
4), induced therapeutically significant anti-tumor immunity to
a poorly immunogenic carcinoma treated with local radiother-
apy, while each treatment by itself was not effective (Demaria
et al., 2005). In addition, radiation induces effects that can
dampen the immune response, like the activation of transform-
ing growth factor (TGF)β (Jobling et al., 2006), and a relative
increase in regulatory T cells (Kachikwu et al., 2011). Altogether,
the pre-existing balance between tolerogenic and effector anti-
tumor mediators, and the degree to which radiation can induce
activation without stimulating suppression, converge to deter-
mine the outcome in terms of local and systemic tumor control.
Intriguingly, there is at least some evidence that the type of
the radiation regimen employed may have a role in determin-
ing whether a favorable pro-immunogenic response is elicited
(Dewan et al., 2009).
HARNESSING THE PRO-IMMUNOGENIC EFFECTS OF
RADIATION IN CANCER TREATMENT: A NEW PARADIGM
Progress in understanding the function and dysfunction of the
immune system in cancer has identified specific targets for inter-
vention, based on the dominant immunosuppressive mechanism
in a given tumor type and/or patient (Zitvogel et al., 2011).
The growing evidence that local radiotherapy can generate an
in situ vaccine supports its use in concert with personalized
immunotherapy, since the killed tumor cells provide the entire
antigenic diversity of a patient’s own tumor.
Since DC function is often suboptimal in tumors, studies have
tested strategies to increase DC numbers and function by admin-
istering DC growth factors in combination with radiotherapy.
Experimental work in two syngeneic mouse models, a lung and a
mammary carcinoma, employed Flt-3 ligand as growth factor to
expand DC, and demonstrated the induction of a T cell-mediated
response that reduced tumor growth outside the field of radia-
tion (Chakravarty et al., 1999; Demaria et al., 2004). Based on
this data, we conducted a clinical trial that used s.c. GM-CSF to
increase the percentage of DC and their maturation and facili-
tate cross-presentation of newly released antigens, after cell death
at the site of radiotherapy. We selected patients with at least 3
metastatic sites from solid tumors.With a standard radiation frac-
tionation of 3.5 Gy X10 fractions delivered to one tumor site we
were able to measure an out-of field (abscopal) response in 30%
of the patients with metastatic solid tumors accrued to the trial
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FIGURE 1 | Ionizing radiation acts as a modifier of the tumor
microenvironment converting the tumor into an in situ vaccine.
Radiation induces an immunogenic cell death of tumor cells characterized by
calreticulin translocation to the surface of dying cells, and release of HMGB-1
and ATP. Calreticulin allows uptake of dying cells by dendritic cells via
scavenger receptor(s). HMGB-1 binds to TLR4 and promotes the
cross-presentation of tumor antigens, while ATP binds to P2X7 and triggers
the activation of the inflammasome. Activated dendritic cells migrate to the
draining lymph node, where they activate naïve T cells specific for tumor
antigens. Activated CD8 T cells acquire effector functions and traffic to the
tumor guided by radiation-induced chemokines. Tumor infiltration by CTLs is
facilitated by radiation-induced upregulation of VCAM-1 on the vascular
endothelium. Once in the tumor, CTLs interact efficiently with tumor cells
expressing increased levels of MHC-I, ICAM-1, NKG2D ligands, and Fas that
promote the formation of stable immunological synapses between targets
and effectors and facilitate the killing of tumor cells by CTLs. Tumor cells
killed by CTLs become a source of antigens for cross-presentation, thus
fueling the process.
(Formenti and Demaria, 2009). In murine models, exogenously
prepared DC injected in the tumor following radiation induced
anti-tumor immune responses (Nikitina and Gabrilovich, 2001;
Teitz-Tennenbaum et al., 2003; Kim et al., 2004). These effects
were translated in the majority of patients with hepatoma and
high risk sarcoma treated in two early clinical trials (Chi et al.,
2005; Finkelstein et al., 2012). In preclinical models molecu-
lar mimics of the danger signals associated with pathogens, like
olygodeoxynucleotides containing CpGmotifs that bind to TLR9,
when injected intratumorally enhanced DC activation and ability
to cross-present tumor antigens released by radiation (Milas et al.,
2004; Mason et al., 2005). A similar combination of local radio-
therapy and CpG administration was tested in 15 patients with
low-grade B-cell lymphoma, showing abscopal responses, asso-
ciated with development of tumor-specific T cells (Brody et al.,
2010). Taken together, the data support the ability of radiation to
generate an in situ vaccine: the efficacy of this approach is depen-
dent on DC fitness and can be enhanced by interventions directed
at improving DC.
A complementary strategy is based on targeting checkpoint co-
inhibitory receptors or co-stimulatory receptors expressed by T
cells with blocking or agonistic antibodies, respectively, to achieve
stronger and more sustained responses of anti-tumor T cells.
Our group tested the hypothesis that inhibiting a key checkpoint
receptor, CTLA-4, in combination with radiotherapy would
induce therapeutically effective anti-tumor responses. While
CTLA-4 is a dominant inhibitory receptor for T cells, as demon-
strated by the development of uncontrolled T cell proliferation
in mice deficient in CTLA-4 (Chambers et al., 1997), CTLA-4
blockade as monotherapy failed to induce regression of poorly
immunogenic tumors, requiring its use in combination with vac-
cination (Peggs et al., 2008). Therefore, we hypothesized that
radiotherapy would synergize with anti-CTLA-4, due to its abil-
ity to generate an in situ vaccine. This hypothesis was confirmed
in mice models of poorly immunogenic carcinomas (Demaria
et al., 2005; Dewan et al., 2009). The therapeutic efficacy of the
anti-tumor T cells activated by treatment was enhanced by other
effects of radiation such as an improved tumor infiltration by
effector T cells, confirming it’s beneficial effects at both the prim-
ing and effector phase of anti-tumor responses (Matsumura et al.,
2008). A recent case report suggests that the success of the com-
bination of local radiotherapy and anti-CTLA-4 can be translated
in melanoma patients (Postow et al., 2012), with multiple clinical
trials being conducted to confirm these results.
Targeting of other co-stimulatory or co-inhibitory receptors
expressed by T cells, CD137 and programmed death (PD)-1,
respectively, has also shown some success in combination with
radiation in mice models (Newcomb et al., 2010; Verbrugge et al.,
2012), supporting more studies to develop these strategies for
clinical use.
Frontiers in Oncology | Molecular and Cellular Oncology August 2012 | Volume 2 | Article 95 | 4
Demaria and Formenti T-cell dependent radiation response
A number of other studies exploited the pro-immunogenic
effects of local radiotherapy that promote the effector phase of
tumor rejection, by combining radiation with either vaccina-
tion or adoptive immune therapy (AIT). Increased expression of
MHC class I antigens by irradiated glioma cells was implicated
in the synergy of peripheral vaccination with whole brain radi-
ation (Newcomb et al., 2006). In a mouse carcinoma, radiation-
induced Fas expression was shown to synergize with T cell AIT
and with vaccination, by facilitating tumor cell killing by T cells
(Chakraborty et al., 2003, 2004). Interestingly, following the com-
bination of vaccine and local radiation there was an induction
of T cells specific for tumor antigens not present in the vaccine,
a phenomenon known as antigen cascade or antigenic spread.
Similarly, antigen cascade was also observed in prostate can-
cer patients treated with standard definitive radiotherapy and
vaccination (Gulley et al., 2005).
CONCLUSIONS
Immune response modifiers (IRM) have been defined by the
National Cancer Institute Translational Research Working Group
as “immunotherapy agents that mimic, augment, or require
participation of the host immune system for optimal effective-
ness” (Cheever et al., 2008). Although host T cells contribution
to the optimal tumor response to radiation was demonstrated
over three decades ago (Stone et al., 1979), it is only in the last
decade that the underlying mechanisms begun to be understood.
Increasing number of publications testing new combinations of
radiation and immunotherapy testify to the growing interest
toward a new role of radiation as an “immunological adjuvant”.
Most exciting is the emerging evidence that radiation may indeed
function as an IRM in patients, suggesting that it may be time to
consider a paradigm shift in the use of radiotherapy.
ACKNOWLEDGMENTS
The authors would like to thank Dr. Lorenzo Agoni for designing
the figure in this manuscript. The authors are supported by grants
from NIH, R01 CA113851 (Sandra Demaria) and R01 CA161891
(Silvia C. Formenti), The Chemotherapy Foundation (Sandra
Demaria), USA Department of Defense Breast Cancer Research
Program BC100481 (Silvia C. Formenti and Sandra Demaria).
REFERENCES
Apetoh, L., Ghiringhelli, F., Tesniere,
A., Obeid, M., Ortiz, C., Criollo,
A., Mignot, G., Maiuri, M. C.,
Ullrich, E., Saulnier, P., Yang, H.,
Amigorena, S., Ryffel, B., Barrat, F.
J., Saftig, P., Levi, F., Lidereau, R.,
Nogues, C., Mira, J. P., Chompret,
A., Joulin, V., Clavel-Chapelon, F.,
Bourhis, J., André, F., Delaloge,
S., Tursz, T., Kroemer, G., and
Zitvogel, L. (2007). Toll-like recep-
tor 4-dependent contribution of
the immune system to anticancer
chemotherapy and radiotherapy.
Nat. Med. 13, 1050–1059.
Brody, J. D., Ai, W. Z., Czerwinski,
D. K., Torchia, J. A., Levy, M.,
Advani, R. H., Kim, Y. H., Hoppe,
R. T., Knox, S. J., Shin, L. K.,
Wapnir, I., Tibshirani, R. J., and
Levy, R. (2010). In situ vaccina-
tion with a TLR9 agonist induces
systemic lymphoma regression: a
phase I/II study. J. Clin. Oncol. 28,
4324–4332.
Buckowitz, A., Knaebel, H. P., Benner,
A., Bläker, H., Gebert, J., Kienle,
P., von Knebel Doeberitz, M., and
Kloor, M. (2005). Microsatellite
instability in colorectal cancer is
associated with local lymphocyte
infiltration and low frequency of
distant metastases. Br. J. Cancer 92,
1746–1753.
Chakraborty, M., Abrams, S. I.,
Camphausen, K., Liu, K., Scott,
T., Coleman, C. N., and Hodge, J.
W. (2003). Irradiation of tumor
cells up-regulates Fas and enhances
CTL lytic activity and CTL adoptive
immunotherapy. J. Immunol. 170,
6338–6347.
Chakraborty, M., Abrams, S. I.,
Coleman, C. N., Camphausen,
K., Schlom, J., and Hodge, J. W.
(2004). External beam radiation of
tumors alters phenotype of tumor
cells to render them susceptible
to vaccine-mediated T-cell killing.
Cancer Res. 64, 4328–4337.
Chakravarty, P. K., Alfieri, A., Thomas,
E. K., Beri, V., Tanaka, K. E.,
Vikram, B., and Guha, C. (1999).
Flt3-Ligand administration after
radiation therapy prolongs survival
in a murine model of metastatic
lung cancer. Cancer Res. 59,
6028–6032.
Chambers, C. A., Sullivan, T.
J., and Allison, J. P. (1997).
Lymphoproliferation in CTLA-
4-deficient mice is mediated by
costimulation-dependent activation
of CD4+ T cells. Immunity 7,
885–895.
Chang, C. C., and Ferrone, S. (2007).
Immune selective pressure and
HLA class I antigen defects in
malignant lesions. Cancer Immunol.
Immunother. 56, 227–236.
Cheever, M. A., Schlom, J., Weiner,
L. M., Lyerly, H. K., Disis, M. L.,
Greenwood, A., Grad, O., Nelson,
W. G., and Group, T. R. W. (2008).
Translational Research Working
Group developmental pathway for
immune response modifiers. Clin.
Cancer Res. 14, 5692–5699.
Chen, Q., Wang, W. C., and Evans, S.
S. (2003). Tumor microvasculature
as a barrier to antitumor immunity.
Cancer Immunol. Immunother. 52,
670–679.
Chi, K. H., Liu, S. J., Li, C. P., Kuo,
H. P., Wang, Y. S., Chao, Y., and
Hsieh, S. L. (2005). Combination of
conformal radiotherapy and intra-
tumoral injection of adoptive den-
dritic cell immunotherapy in refrac-
tory hepatoma J. Immunother. 28,
129–135.
Chiaravalli, A. M., Feltri, M., Bertolini,
V., Bagnoli, E., Furlan, D., Cerutti,
R., Novario, R., and Capella, C.
(2006). Intratumour T cells, their
activation status and survival in
gastric carcinomas characterised
for microsatellite instability and
Epstein-Barr virus infection.
Virchows Arch. 448, 344–353.
Demaria, S. (2012) “Immune escape:
immunosuppressive networks,” in
Cancer Immunotherapy, eds G. C.
Prendergast and E. M. Jaffee (New
York, NY: Elsevier Inc.).
Demaria, S., and Formenti, S. C.
(2007). Sensors of ionizing radia-
tion effects on the immunological
microenvironment of cancer. Int. J.
Radiat. Biol. 83, 819–825.
Demaria, S., Kawashima, N., Yang,
A. M., Devitt, M.-L., Babb, J.
S., Allison, J. P., and Formenti,
S. C. (2005). Immune-mediated
inhibition of metastases following
treatment with local radiation and
CTLA-4 blockade in a mouse model
of breast cancer. Clin. Cancer Res.
11, 728–734.
Demaria, S., Ng, B., Devitt, M.-L.,
Babb, J. S., Kawashima, N., Liebes,
L., and Formenti, S. C. (2004).
Ionizing radiation inhibition of dis-
tant untreated tumors (abscopal
effect) is immune mediated. Int.
J. Radiat. Oncol. Biol. Phys. 58,
862–870.
Dewan, M. Z., Galloway, A. E.,
Kawashima, N., Dewyngaert, J. K.,
Babb, J. S., Formenti, S. C., and
Demaria, S. (2009). Fractionated
but not single dose radiotherapy
induces an immune-mediated
abscopal effect when combined
with anti-CTLA-4 antibody. Clin.
Cancer Res. 15, 5379–5388.
Diefenbach, A., Jamieson, A. M., Liu,
S. D., Shastri, N., and Raulet,
D. H. (2000). Ligands for the
murine NKG2D receptor: expres-
sion by tumor cells and activation
of NK cells and macrophages Nat.
Immunol. 1, 119–126.
Dong, H., Strome, S. E., Salomao, D. R.,
Tamura, H., Hirano, F., Flies, D. B.,
Roche, P. C., Lu, J., Zhu, G., Tamada,
K., Lennon, V. A., Celis, E., and
Chen, L. (2002). Tumor-associated
B7-H1 promotes T-cell apoptosis:
a potential mechanism of immune
evasion. Nat. Med. 8, 793–800.
DuPage, M., Mazumdar, C., Schmidt,
L. M., Cheung, A. F., and Jacks,
T. (2012). Expression of tumour-
specific antigens underlies cancer
immunoediting Nature 482,
405–409.
Dunn, G. P., Bruce, A. T., Ikeda,
H., Old, L. J., and Schreiber, R.
D. (2002). Cancer immunoedit-
ing: from immunosurveillance to
tumor escape. Nat. Immunol. 3,
991–998.
www.frontiersin.org August 2012 | Volume 2 | Article 95 | 5
Demaria and Formenti T-cell dependent radiation response
Dunn, G. P., Koebel, C. M., and
Schreiber, R. D. (2006). Interferons,
immunity and cancer immu-
noediting. Nat. Rev. Immunol. 6,
836–848.
Dunn, G. P., Old, L. J., and Schreiber,
R. D. (2004). The three Es of
cancer immunoediting. Annu. Rev.
Immunol. 22, 329–360.
Finkelstein, S. E., Iclozan, C., Bui, M.
M., Cotter, M. J., Ramakrishnan, R.,
Ahmed, J., Noyes, D. R., Cheong,
D., Gonzalez, R. J., Heysek, R.
V., Berman, C., Lenox, B. C.,
Janssen, W., Zager, J. S., Sondak,
V. K., Letson, G. D., Antonia, S.
J., and Gabrilovich, D. I. (2012).
Combination of external beam
radiotherapy (EBRT) with intratu-
moral injection of dendritic cells as
neo-adjuvant treatment of high-risk
soft tissue sarcoma patients Int.
J. Radiat. Oncol. Biol. Phys. 82,
924–932.
Formenti, S. C., and Demaria, S.
(2009). Systemic effects of local
radiotherapy. Lancet Oncol. 10,
718–726.
Galluzzi, L., Maiuri, M. C., Vitale, I.,
Zischka, H., Castedo, M., Zitvogel,
L., and Kroemer, G. (2007). Cell
death modalities: classification and
pathophysiological implications.
Cell Death Differ. 14, 1237–1243.
Galon, J., Costes, A., Sanchez-Cabo, F.,
Kirilovsky, A., Mlecnik, B., Lagorce-
Pages, C., Tosolini, M., Camus, M.,
Berger, A., Wind, P., Zinzindohoue,
F., Bruneval, P., Cugnenc, P. H.,
Trajanoski, Z., Fridman, W. H.,
and Pages, F. (2006). Type, den-
sity, and location of immune cells
within human colorectal tumors
predict clinical outcome. Science
313, 1960–1964.
Ganss, R., Ryschich, E., Klar, E., Arnold,
B., and Hammerling, G. J. (2002).
Combination of T-cell therapy and
trigger of inflammation induces
remodeling of the vasculature and
tumor eradication Cancer Res. 62,
1462–1470.
Garnett, C. T., Palena, C., Chakarborty,
M., Tsang, K. Y., Schlom, J., and
Hodge, J. W. (2004). Sublethal
irradiation of human tumor cells
modulates phenotype resulting
in enhanced killing by cytotoxic
T lymphocytes. Cancer Res. 64,
7985–7994.
Gasser, S., Orsulic, S., Brown, E. J.,
and Raulet, D. H. (2005). The
DNA damage pathway regulates
innate immune system ligands of
the NKG2D receptor. Nature 436,
1186–1190.
Gaugler, M. H., Squiban, C., van
der Meeren, A., Bertho, J. M.,
Vandamme, M., and Mouthon,
M. A. (1997). Late and persis-
tent up-regulation of intercellular
adhesion molecule-1 (ICAM-1)
expression by ionizing radiation in
human endothelial cells in vitro. Int.
J. Radiat. Biol. 72, 201–209.
Ghiringhelli, F., Apetoh, L., Tesniere,
A., Aymeric, L., Ma, Y., Ortiz,
C., Vermaelen, K., Panaretakis, T.,
Mignot, G., Ullrich, E., Perfettini,
J. L., Schlemmer, F., Tasdemir, E.,
Uhl, M., Génin, P., Civas, A., Ryffel,
B., Kanellopoulos, J., Tschopp, J.,
André, F., Lidereau, R., McLaughlin,
N. M., Haynes, N. M., Smyth, M.
J., Kroemer, G., and Zitvogel, L.
(2009). Activation of the NLRP3
inflammasome in dendritic cells
induces IL-1beta-dependent adap-
tive immunity against tumors. Nat.
Med. 15, 1170–1178.
Gulley, J. L., Arlen, P. M., Bastian, N.,
Morin, N., Marte, J., Beetham, P.,
Tsang, K.-Y., Yokokawa, J., Hodge,
J. W., Menard, C., Camphausen,
K., Coleman, C. N., Sullivan, F.,
Steinberg, S. M., Schlom, J., and
Dahut, P. (2005). Combining a
recombinant cancer vaccine with
standard definitive radiotherapy in
patients with localized prostate can-
cer. Clin. Cancer Res. 11, 3353–3362.
Hanahan, D., and Weinberg, R. A.
(2000). The hallmarks of cancer Cell
100, 57–70.
Hanahan, D., and Weinberg, R. A.
(2011). Hallmarks of cancer: the
next generation. Cell 144, 646–674.
Hareyama, M., Imai, K., Kubo, K.,
Takahashi, H., Koshiba, H., Hinoda,
Y., Shidou, M., Oouchi, A., Yachi,
A., and Morita, K. (1991). Effect
of radiation on the expression
of carcinoembryonic antigen of
human gastric adenocarcinoma
cells. Cancer 67, 2269–2274.
Hayakawa, Y., Kelly, J. M., Westwood,
J. A., Darcy, P. K., Diefenbach, A.,
Raulet, D., and Smyth, M. J. (2002).
Cutting edge: tumor rejection medi-
ated by NKG2D receptor-ligand
interaction is dependent upon per-
forin J. Immunol. 169, 5377–5381.
Hodi, F. S., O’Day, S. J., McDermott,
D. F., Weber, R. W., Sosman, J. A.,
Haanen, J. B., Gonzalez, R., Robert,
C., Schadendorf, D., Hassel, J. C.,
Akerley, W., van den Eertwegh, A.
J., Lutzky, J., Lorigan, P., Vaubel,
J. M., Linette, G. P., Hogg, D.,
Ottensmeier, C. H., Lebbé, C.,
Peschel, C., Quirt, I., Clark, J.
I., Wolchok, J. D., Weber, J. S.,
Tian, J., Yellin, M. J., Nichol, G.
M., Hoos, A., and Urba, W. J.
(2010). Improved survival with ipil-
imumab in patients with metastatic
melanoma. N. Engl. J. Med. 363,
711–723.
Janeway, C. A. J., and Medzhitov, R.
(2002). Innate immune recognition.
Annu. Rev. Immunol. 20, 197–216.
Jobling, M. F., Mott, J. D., Finnegan,
M. T., Jurukovski, V., Erickson,
A. C., Walian, P. J., Taylor, S.
E., Ledbetter, S., Lawrence, C. M.,
Rifkin, D. B., and Barcellos-Hoff, M.
H. (2006). Isoform-specific activa-
tion of latent transforming growth
factor beta (LTGF-beta) by reac-
tive oxygen species. Radiat. Res. 166,
839–848.
Kachikwu, E. L., Iwamoto, K. S., Liao,
Y. P., DeMarco, J. J., Agazaryan, N.,
Economou, J. S., McBride, W. H.,
and Schaue, D. (2011). Radiation
enhances regulatory T cell represen-
tation. Int. J. Radiat. Oncol. Biol.
Phys. 81, 1128–1135.
Kim, J. Y., Son, Y. O., Park, S. W.,
Bae, J. H., Chung, J. S., Kim, H.
H., Chung, B. S., Kim, S. H., and
Kang, C. D. (2006). Increase of
NKG2D ligands and sensitivity to
NK cell-mediated cytotoxicity of
tumor cells by heat shock and ion-
izing radiation. Exp. Mol. Med. 38,
474–484.
Kim, K. W., Kim, S. H., Shin, J. G., Kim,
G. S., Son, Y. O., Park, S. W., Kwon,
B. H., Kim, D.W., Lee, C. H., Sol, M.
Y., Jeong, M. H., Chung, B. S., and
Kang, C. D. (2004). Direct injec-
tion of immature dendritic cells into
irradiated tumor induces efficient
antitumor immunity. Int. J. Cancer
109, 685–690.
Koebel, C. M., Vermi, W., Swann, J. B.,
Zerafa, N., Rodig, S. J., Old, L. J.,
Smyth, M. J., and Schreiber, R. D.
(2007). Adaptive immunity main-
tains occult cancer in an equilib-
rium state. Nature 450, 903–907.
Lotze, M. T., Zeh, H. J., Rubartelli, A.,
Sparvero, L. J., Amoscato, A. A.,
Washburn, N. R., Devera, M. E.,
Liang, X., Tör, M., and Billiar, T.
(2007). The grateful dead: damage-
associated molecular pattern
molecules and reduction/oxidation
regulate immunity. Immunol. Rev.
220, 60–81.
Lugade, A. A., Moran, J. P., Gerber, S.
A., Rose, R. C., Frelinger, J. G., and
Lord, E. M. (2005). Local radiation
therapy of B16 melanoma tumors
increases the generation of tumor
antigen-specific effector cells that
traffic to the tumor. J. Immunol. 174,
7516–7523.
Lugade, A. A., Sorensen, E. W., Gerber,
S. A., Moran, J. P., Frelinger,
J. G., and Lord, E. M. (2008).
Radiation-induced IFN-gamma
production within the tumor
microenvironment influences anti-
tumor immunity J. Immunol. 180,
3132–3139.
Ma, Y., Kepp, O., Ghiringhelli, F.,
Apetoh, L., Aymeric, L., Locher,
C., Tesniere, A., Martins, I., Ly,
A., Haynes, N. M., Smyth, M.
J., Kroemer, G., and Zitvogel,
L. (2010). Chemotherapy and
radiotherapy: cryptic anticancer
vaccines. Semin. Immunol. 22,
113–124.
MacKie, R. M., Reid, R., and Junor, B.
(2003). Fatal melanoma transferred
in a donated kidney 16 years after
melanoma surgery N. Engl. J. Med.
348, 567–568.
Mason, K. A., Ariga, H., Neal, R.,
Valdecanas, D., Hunter, N., Krieg, A.
M., Whisnant, J. K., and Milas, L.
(2005). Targeting toll-like receptor
9 with CpG oligodeoxynucleotides
enhances tumor response to frac-
tionated radiotherapy. Clin. Cancer
Res. 11, 361–369.
Matsumura, S., Wang, B., Kawashima,
N., Braunstein, S., Badura, M.,
Cameron, T. O., Babb, J. S.,
Schneider, R. J., Formenti, S. C.,
Dustin, M. L., and Demaria, S.
(2008). Radiation-induced CXCL16
release by breast cancer cells attracts
effector T cells. J. Immunol. 181,
3099–3107.
Matsushita, H., Vesely, M. D., Koboldt,
D. C., Rickert, C. G., Uppaluri,
R., Magrini, V. J., Arthur, C. D.,
White, J. M., Chen, Y. S., Shea,
L. K., Hundal, J., Wendl, M. C.,
Demeter, R., Wylie, T., Allison, J.
P., Smyth, M. J., Old, L. J., Mardis,
E. R., and Schreiber, R. D. (2012).
Cancer exome analysis reveals a T-
cell-dependent mechanism of can-
cer immunoediting. Nature 482,
400–404.
McBride, W. H., Chiang, C.-S., Olson,
J. L., Wang, C.-C., Hong, J.-H.,
Pajonk, F., Dougherty, G. J.,
Iwamoto, K. S., Pervan, M., and
Liao, Y.-P. (2004). A sense of danger
from radiation. Radiat. Res. 162,
1–19.
Michaud, M., Martins, I., Sukkurwala,
A. Q., Adjemian, S., Ma, Y.,
Pellegatti, P., Shen, S., Kepp, O.,
Scoazec, M., Mignot, G., Rello-
Varona, S., Tailler, M., Menger,
L., Vacchelli, E., Galluzzi, L.,
Ghiringhelli, F., Di Virgilio, F.,
Zitvogel, L., and Kroemer, G.
(2011). Autophagy-dependent anti-
cancer immune responses induced
by chemotherapeutic agents in
mice. Science 334, 1573–1577.
Milas, L., Mason, K. A., Ariga, H.,
Hunter, N., Neal, R., Valdecanas,
D., Krieg, A. M., and Whisnant,
J. K. (2004). CpG oligodeoxynu-
cleotide enhances tumor response
to radiation. Cancer Res. 64,
5074–5077.
Frontiers in Oncology | Molecular and Cellular Oncology August 2012 | Volume 2 | Article 95 | 6
Demaria and Formenti T-cell dependent radiation response
Mills, K. H. (2011). TLR-dependent
T cell activation in autoimmunity.
Nat. Rev. Immunol. 11, 807–822.
Mole, R. J. (1953). Whole body
irradiation—radiology or
medicine? Br. J. Radiol. 26, 234–241.
Myron Kauffman, H., McBride,
M. A., Cherikh, W. S., Spain,
P. C., Marks, W. H., and Roza,
A. M. (2002). Transplant tumor
registry: donor related malig-
nancies. Transplantation 74,
358–362.
Newcomb, E. W., Demaria, S.,
Lukyanov, Y., Shao, Y., Schnee,
T., Kawashima, N., Lan, L.,
Dewyngaert, J. K., Zagzag, D.,
McBride, W. H., and Formenti,
S. C. (2006). The combination of
ionizing radiation and peripheral
vaccination produces long-term
survival of mice bearing established
invasive GL261 gliomas. Clin.
Cancer Res. 12, 4730–4737.
Newcomb, E. W., Lukyanov, Y.,
Kawashima, N., Alonso-Basanta,
M., Wang, S.-C., Liu, M., Jure-
Kunkel, M., Zagzag, D., Demaria,
S., and Formenti, S. C. (2010).
Radiotherapy enhances antitumor
effect of anti-CD137 therapy in a
mouse Glioma model. Radiat. Res.
173, 426–432.
Nikitina, E. Y., and Gabrilovich,
D. I. (2001). Combination of
gamma-irradiation and dendritic
cell administration induces a
potent antitumor response in
tumor-bearing mice: approach
to treatment of advanced
stage cancer. Int. J. Cancer 94,
825–833.
Obeid, M., Panaretakis, T., Joza, N.,
Tufi, R., Tesniere, A., van Endert,
P., Zitvogel, L., and Kroemer, G.
(2007). Calreticulin exposure is
required for the immunogenicity
of gamma-irradiation and UVC
light-induced apoptosis Cell Death
Differ. 14, 1848–1850.
Pagès, F., Galon, J., Dieu-Nosjean, M.
C., Tartour, E., Sautès-Fridman,
C., and Fridman, W. H. (2010).
Immune infiltration in human
tumors: a prognostic factor that
should not be ignored. Oncogene
29, 1093–1102.
Peggs, K. S., Quezada, S. A., and
Allison, J. P. (2008). Cell intrin-
sic mechanisms of T-cell inhibition
and application to cancer therapy.
Immunol. Rev. 224, 141–165.
Porter, D. L., Levine, B. L., Kalos,
M., Bagg, A., and June, C. H.
(2011). Chimeric antigen receptor-
modified T cells in chronic lym-
phoid leukemia. N. Engl. J. Med.
365, 725–733.
Postow, M. A., Callahan, M. K., Barker,
C. A., Yamada, Y., Yuan, J., Kitano,
S., Mu, Z., Rasalan, T., Adamow, M.,
Ritter, E., Sedrak, C., Jungbluth, A.
A., Chua, R., Yang, A. S., Roman, R.
A., Rosner, S., Benson, B., Allison, J.
P., Lesokhin, A. M., Gnjatic, S., and
Wolchok, J. D. (2012). Immunologic
correlates of the abscopal effect in a
patient with melanoma. N. Engl. J.
Med. 366, 925–931.
Reits, E. A., Hodge, J. W., Herberts, C.
A., Groothuis, T. A., Chakraborty,
M., Wansley, E. K., Camphausen,
K., Luiten, R. M., de Ru, A.
H., Neijssen, J., Griekspoor, A.,
Mesman, E., Verreck, F. A., Spits,
H., Schlom, J., van Veelen, P.,
and Neefjes, J. J. (2006). Radiation
modulates the peptide repertoire,
enhances MHC class I expression,
and induces successful antitumor
immunotherapy J. Exp. Med. 203,
1259–1271.
Restifo, N. P., Dudley, M. E., and
Rosenberg, S. A. (2012). Adoptive
immunotherapy for cancer: har-
nessing the T cell response. Nat. Rev.
Immunol. 12, 269–281.
Rieber, M., and Rieber, M. S. (2008).
Sensitization to radiation-induced
DNA damage accelerates loss of
bcl-2 and increases apoptosis and
autophagy. Cancer Biol. Ther. 7,
1561–1566.
Rodriguez-Rocha, H., Garcia-Garcia,
A., Panayiotidis, M. I., and Franco,
R. (2011). DNA damage and
autophagy. Mutat. Res. 711,
158–166.
Segal, N. H., Parsons, D. W., Peggs,
K. S., Velculescu, V., Kinzler, K.
W., Vogelstein, B., and Allison, J. P.
(2008). Epitope landscape in breast
and colorectal cancer. Cancer Res.
68, 889–892.
Stone, H. B., Peters, L. J., and Milas, L.
(1979). Effect of host immune capa-
bility on radiocurability and subse-
quent transplantability of a murine
fibrosarcoma. J. Natl. Cancer Inst.
63, 1229–1235.
Street, S. E., Cretney, E., and Smyth, M.
J. (2001). Perforin and interferon-
gamma activities independently
control tumor initiation, growth,
and metastasis. Blood 97, 192–197.
Teitz-Tennenbaum, S., Li, Q.,
Rynkiewicz, S., Ito, F., Davis,
M. A., McGinn, C. J., and Chang, A.
E. (2003). Radiotherapy potentiates
the therapeutic efficacy of intratu-
moral dendritic cell administration.
Cancer Res. 63, 8466–8475.
Verbrugge, I., Hagekyriakou, J.,
Sharp, L. L., Galli, M., West, A.
C., McLaughlin, N. M., Duret,
H., Yagita, H., Johnstone, R. W.,
Smyth, M. J., and Haynes, N. M.
(2012). Radiotherapy increases
the permissiveness of established
mammary tumors to rejection by
immunomodulatory antibodies.
Cancer Res. 72, 3163–3174.
Vesely, M. D., Kershaw, M. H.,
Schreiber, R. D., and Smyth, M. J.
(2011). Natural innate and adaptive
immunity to cancer. Annu. Rev.
Immunol. 29, 235–271.
Zeh, H. Jr., and Lotze, M. T. (2005).
Addicted to death: invasive can-
cer and the immune response
to unscheduled cell death. J.
Immunother. 28, 1–9.
Zhang, L., Conejo-Garcia, J. R.,
Katsaros, D., Gimotty, P. A.,
Massobrio, M., Regnani, G.,
Makrigiannakis, A., Gray, H.,
Schlienger, K., Liebman, M. N.,
Rubin, S. C., and Coukos, G.
(2003). Intratumoral T cells, recur-
rence, and survival in epithelial
ovarian cancer. N. Engl. J. Med. 348,
203–213.
Zitvogel, L., Kepp, O., and Kroemer, G.
(2010). Decoding cell death signals
in inflammation and immunity. Cell
140, 798–804.
Zitvogel, L., Kepp, O., and Kroemer,
G. (2011). Immune parameters
affecting the efficacy of chemother-
apeutic regimens. Nat. Rev. Clin.
Oncol. 8, 151–160.
Conflict of Interest Statement: The
authors declare that the research
was conducted in the absence of any
commercial or financial relationships
that could be construed as a potential
conflict of interest.
Received: 01 June 2012; accepted: 23 July
2012; published online: 24 August 2012.
Citation: Demaria S and Formenti SC
(2012) Role of T lymphocytes in tumor
response to radiotherapy. Front. Oncol.
2:95. doi: 10.3389/fonc.2012.00095
This article was submitted to Frontiers
in Molecular and Cellular Oncology, a
specialty of Frontiers in Oncology.
Copyright © 2012 Demaria and
Formenti. This is an open-access article
distributed under the terms of the
Creative Commons Attribution License,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are
credited and subject to any copyright
notices concerning any third-party
graphics etc.
www.frontiersin.org August 2012 | Volume 2 | Article 95 | 7
